As a global leading contract development and manufacturing organization (CDMO) for cell and gene therapy products, Minaris Regenerative Medicine has been offering our clients high value clinical and commercial manufacturing services, development solutions, and technologies for more than 20 years.
As a global company with facilities in the U.S., Germany, and Japan, we will be shifting to a model of regional operational leadership beginning October 1, 2021. The three regional Chief Operating Officers will collaborate on a Global Functional team. Please read our press release to learn more about those appointed.
Derived from the Japanese word “mirai” meaning future, and the English word “miracle”, meaning “an extraordinary event”, our new name speaks to our goal to exceed the expectations of our customers.Learn More About Us
Our manufacturing development services help you design efficient and robust manufacturing processes for your cell and gene therapy.
We offer a comprehensive manufacturing experience that is fully compliant with the relevant regional regulatory requirements of our global facilities.
Stay up to date with Minaris Regenerative Medicine! View our press releases to read our latest news.
Whether in-person or virtually, read more about the events we will be attending to join our experts, meet our global team, and learn more about how we can help you manufacture your life changing therapeutics!